Stryker Corporation (NYSE:SYK) Stock Has Average Price Target of $370.68

Shares of Stryker Corporation (NYSE:SYK) have been assigned an average rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $369.00.

A number of brokerages have issued reports on SYK. BTIG Research cut their price target on Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Citigroup cut their target price on Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a research report on Thursday, September 10th. Finally, Piper Sandler decreased their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

A number of hedge funds have recently made changes to their positions in SYK. Banque Pictet & Cie SA grew its stake in Stryker by 0.5% in the third quarter. Banque Pictet & Cie SA now owns 189,206 shares of the medical technology company’s stock worth $52,105,000 after purchasing an additional 882 shares in the last quarter. V Square Quantitative Management LLC increased its stake in shares of Stryker by 1.7% during the third quarter. V Square Quantitative Management LLC now owns 8,276 shares of the medical technology company’s stock valued at $2,279,000 after buying an additional 141 shares during the period. Perpetual Ltd increased its stake in shares of Stryker by 17,298.2% during the third quarter. Perpetual Ltd now owns 338,569 shares of the medical technology company’s stock valued at $93,239,000 after buying an additional 336,623 shares during the period. Rockland Trust Co. raised its holdings in shares of Stryker by 1.1% in the third quarter. Rockland Trust Co. now owns 3,365 shares of the medical technology company’s stock valued at $927,000 after acquiring an additional 36 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. raised its holdings in shares of Stryker by 22.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 10,436 shares of the medical technology company’s stock valued at $3,286,000 after acquiring an additional 1,915 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Stryker stock traded up $1.10 during midday trading on Friday, hitting $294.33. The stock had a trading volume of 3,377,322 shares, compared to its average volume of 2,587,815. The firm’s fifty day moving average is $299.31 and its two-hundred day moving average is $312.85. The company has a market capitalization of $112.90 billion, a PE ratio of 30.50, a P/E/G ratio of 1.86 and a beta of 0.78. Stryker has a 52-week low of $267.00 and a 52-week high of $392.55. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker will post 14.95 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.